Mark Tullij Ciceron Tri Traktata Ob Oratorskom Iskusstve Pdf

Over 1990s and early 2000s, the town accepted thousands of Russian Jewish immigrants and Ethiopian. Tiski chertezh autocad. In what became known as the, 22 of these school children were among those killed by the hostage takers after the school had been raided by a special forces unit of the. The city was fully under the control of Jewish paramilitary forces by May 11, 1948. Druze parading in Safed after the victory in 1948 State of Israel [ ] In 1974, 102 Israeli Jewish school children from Safed on a school trip were taken hostage by a Palestinian militant group (DFLP) while sleeping in a school in.

This is a clinical trial designed to assess the cardiovascular outcome of long-term treatment with sitagliptin used as part of usual care compared to usual care without sitagliptin in participants with type 2 diabetes mellitus (T2DM) having a history of cardiovascular (CV) disease and a hemoglobin A1c (HbA1c) of 6.5% to 8.0%. Primary hypothesis A is that sitagliptin, when used as part of usual care, is non-inferior to usual care without sitagliptin with regard to the risk of developing a confirmed event in the primary CV composite endpoint of Major Adverse Cardiovascular Event (MACE) plus. If hypothesis A is satisfied: hypothesis B is that sitagliptin, when used as part of usual care, is superior to usual care without sitagliptin with regard to the risk of developing a confirmed event in the primary CV composite endpoint. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Sitagliptin Drug: Placebo Phase 3. Layout table for study information Study Type: Interventional (Clinical Trial) Actual Enrollment: 14671 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Actual Study Start Date: December 10, 2008 Actual Primary Completion Date: March 30, 2015 Actual Study Completion Date: March 30, 2015. Layout table for additonal information Responsible Party: Merck Sharp & Dohme Corp.

ClinicalTrials.gov Identifier: Other Study ID Numbers: 0431-082 2008_523 ( Other Identifier: Merck study number ) 2008-006719-20 ( EudraCT Number ) First Posted: November 13, 2008 Results First Posted: April 15, 2016 Last Update Posted: August 17, 2018 Last Verified: July 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes Plan Description: URL: Additional relevant MeSH terms.

Mark Tullij Ciceron. Tri traktata ob oratorskom iskusstve. Moskva: Nauka, 1972. Bivalentnist rymskoyi pravovoyi diysnosti.